受强制性开放获取政策约束的文章 - Yelena Y. Janjigian, MD了解详情
无法在其他位置公开访问的文章：4 篇
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 …
YY Janjigian, A Kawazoe, Y Bai, J Xu, S Lonardi, JP Metges, P Yanez, ...
The Lancet 402 (10418), 2197-2208, 2023
强制性开放获取政策： US National Institutes of Health
Total gastrectomy for hereditary diffuse gastric cancer at a single center: postsurgical outcomes in 41 patients
VE Strong, S Gholami, MA Shah, LH Tang, YY Janjigian, M Schattner, ...
Annals of Surgery 266 (6), 1006-1012, 2017
强制性开放获取政策： US National Institutes of Health
Should chemoradiotherapy be standard to maximise cure in localised gastro-oesophageal cancer?
JV Reynolds, D Cowzer, YY Janjigian
The Lancet Oncology 23 (7), 847-849, 2022
强制性开放获取政策： US Department of Defense, US National Institutes of Health
Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma
RH Moy, M Greally, JF Chou, J Li, AM Desai, SB Chalasani, E Won, ...
Cancer Chemotherapy and Pharmacology 89 (2), 255-265, 2022
强制性开放获取政策： US National Institutes of Health, Damon Runyon Cancer Research Foundation
可在其他位置公开访问的文章：131 篇
Comprehensive molecular characterization of gastric adenocarcinoma
Cancer Genome Atlas Research Network
Nature 513 (7517), 202, 2014
强制性开放获取政策： US National Institutes of Health
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
强制性开放获取政策： US National Institutes of Health
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ...
Nature medicine 23 (6), 703-713, 2017
强制性开放获取政策： US National Institutes of Health
OncoKB: a precision oncology knowledge base
D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ...
JCO precision oncology 1, 1-16, 2017
强制性开放获取政策： US National Institutes of Health
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised …
YY Janjigian, K Shitara, M Moehler, M Garrido, P Salman, L Shen, ...
The Lancet 398 (10294), 27-40, 2021
强制性开放获取政策： US National Institutes of Health, Federal Ministry of Education and Research …
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation
K Takezawa, V Pirazzoli, ME Arcila, CA Nebhan, X Song, E de Stanchina, ...
Cancer discovery 2 (10), 922-933, 2012
强制性开放获取政策： US National Institutes of Health
CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer
YY Janjigian, J Bendell, E Calvo, JW Kim, PA Ascierto, P Sharma, PA Ott, ...
Journal of Clinical Oncology 36 (28), 2836-2844, 2018
强制性开放获取政策： US National Institutes of Health, Cancer Research UK
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
YY Janjigian, A Kawazoe, P Yañez, N Li, S Lonardi, O Kolesnik, ...
Nature 600 (7890), 727-730, 2021
强制性开放获取政策： US National Institutes of Health
Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer
A Latham, P Srinivasan, Y Kemel, J Shia, C Bandlamudi, D Mandelker, ...
Journal of clinical oncology 37 (4), 286-295, 2019
强制性开放获取政策： US National Institutes of Health
Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies
JJ Harding, S Nandakumar, J Armenia, DN Khalil, M Albano, M Ly, J Shia, ...
Clinical Cancer Research 25 (7), 2116-2126, 2019
强制性开放获取政策： US National Institutes of Health
Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
YY Janjigian, EF Smit, HJM Groen, L Horn, S Gettinger, DR Camidge, ...
Cancer discovery 4 (9), 1036-1045, 2014
强制性开放获取政策： US National Institutes of Health
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ...
Cell 185 (3), 563-575. e11, 2022
强制性开放获取政策： US National Institutes of Health
Molecular classification of gastric cancer: a new paradigm
MA Shah, R Khanin, L Tang, YY Janjigian, DS Klimstra, H Gerdes, ...
Clinical cancer research 17 (9), 2693-2701, 2011
强制性开放获取政策： US National Institutes of Health
Genetic predictors of response to systemic therapy in esophagogastric cancer
YY Janjigian, F Sanchez-Vega, P Jonsson, WK Chatila, JF Hechtman, ...
Cancer discovery 8 (1), 49-58, 2018
强制性开放获取政策： US Department of Defense, US National Institutes of Health
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
YY Janjigian, SB Maron, WK Chatila, B Millang, SS Chavan, C Alterman, ...
The Lancet Oncology 21 (6), 821-831, 2020
强制性开放获取政策： US Department of Defense, US National Institutes of Health
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
K Shitara, JA Ajani, M Moehler, M Garrido, C Gallardo, L Shen, ...
Nature 603 (7903), 942-948, 2022
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定